Previous Page  5 / 6 Next Page
Information
Show Menu
Previous Page 5 / 6 Next Page
Page Background

Volume 3, Issue 2 (Suppl)

J Aesthet Reconstr Surg, an open access journal

ISSN:2472-1905

Plastic Aesthetic Surgery 2017

July 27-28, 2017

Page 42

conference

series

.com

July 27-28, 2017 Vancouver, Canada

Plastic & Aesthetic Surgery

2

nd

International Conference on

Aziz Ghahary, J Aesthet Reconstr Surg. 2017, 3:2

DOI: 10.4172/2472-1905-C1-001

Aziz Ghahary

BC Professional Firefighters Burn and Wound Healing Research Group, Canada

A novel wound dressings with anti-scarring properties

Background:

Wound healing outcome is regulated by a fine balance between deposition and degradation of extracellular matrix

(ECM). Over healing process in skin is mediated by exaggerated ECM deposition and abnormalities in ECM degradation.

Current treatment modalities for prevention of burn hypertrophic scarring has limited efficacy which raised a great need for

innovation within wound care industry. Moving towards novel approaches to prevent post burn hypertrophic scarring, we

identified the anti-scarring properties of Kynurenine (Kyn), a naturally occurring small molecule generated from tryptophan

degradation. Although daily application of Kyn containing cream prevents scarring in a rabbit ear model, an effective wound

dressing, slowly releasing controlled doses of Kyn, will be more beneficial for Kyn delivery to extensive burns, where the

dressings get changed every 4-5 days.

Aim:

This study aims to develop a new generation of wound dressings having anti-scarring properties.

Methods:

The Effect of Kyn treatment on the expression of different ECM components, collagen type-I, fibronectin and

MMP1 and 3 was evaluated. Wound dressings were manufactured by incorporating Kyn into PVA/PLGA nanofibers using

electrospinning process. Drug release profile was determined by incubating the electrospun mats in PBS. The anti-scarring

properties of these nanofibrous wound dressings were evaluated

in vitro

and

in vivo

.

Results:

In vitro

studies showed that while Kyn doesn’t have any adverse effect on the dermal cells’ viability, it significantly

decreases the expression of collagen type-I and fibronectin and increases the expression of MMP1, which is a collagenase, and

MMP3. Whereas, the Kyn-loaded PVA demonstrated immediate and complete drug release of the drug, addition of PLGA

envelop via dip-coating significantly reduced the burst release, due to added tortuosity and increased hydrophobicity of the

shell.

In vivo

studies showed that wound treatment with Kyn-loaded dressings significantly improves the wound healing

outcome and eliminates evidence of scarring in the rat excisional wounds.

Conclusions:

Anti-fibrotic effects of Kyn are mediated by increasing the expression of MMPs and reducing the production

of ECM components

in vitro

and

in vivo

. This study sets the stage for development of a new generation of wound dressings

facilitating the controlled and prolonged release of this anti-scarring drug.

Applicability of Research to Practice:

These wound dressings can improve/prevent fibrotic conditions developed upon burn,

trauma and surgical procedures without compromising the health of the patient.

Biography

Aziz Ghahary, PhD and a Professor, is the Director of the BC Professional Firefighters ‘Burn and Wound Healing Research Group. He has published more than 168

peer-reviewed articles some of which are directly related to autoimmune diseases such as type I diabetes. He has been awarded more than 50 research grants from differ-

ent local, national and international granting agencies. He is the leading investigator in identifying a serum 14-3-3 eta protein as a biomarker for early detection of RA and

psoriatic RA and this test has now been launched by the Quest Diagnosis and Lifelab in US and Canada, respectively. Finally, he recently identified a small molecule with

anti-scaring properties, which has now been approved by the Health Canada and the Vancouver General Hospital Ethic Committee to proceed to Phase 1 Clinical Trial.

aghahary@mail.ubc.ca